S&P 500   3,665.00 (+1.20%)
DOW   29,849.45 (+0.71%)
QQQ   303.34 (+1.24%)
AAPL   122.56 (+2.95%)
MSFT   215.83 (+0.82%)
FB   286.45 (+3.42%)
GOOGL   1,794.91 (+2.31%)
AMZN   3,209.81 (+1.32%)
TSLA   582.30 (+2.59%)
NVDA   535.32 (-0.14%)
BABA   263.17 (-0.07%)
CGC   26.72 (-7.22%)
GE   10.12 (-0.59%)
MU   67.07 (+4.65%)
AMD   92.64 (-0.02%)
T   28.84 (+0.31%)
NIO   44.79 (-11.36%)
F   9.22 (+1.54%)
ACB   9.74 (-16.61%)
NFLX   502.68 (+2.44%)
BA   213.51 (+1.33%)
GILD   61.12 (+0.74%)
DIS   149.45 (+0.97%)
S&P 500   3,665.00 (+1.20%)
DOW   29,849.45 (+0.71%)
QQQ   303.34 (+1.24%)
AAPL   122.56 (+2.95%)
MSFT   215.83 (+0.82%)
FB   286.45 (+3.42%)
GOOGL   1,794.91 (+2.31%)
AMZN   3,209.81 (+1.32%)
TSLA   582.30 (+2.59%)
NVDA   535.32 (-0.14%)
BABA   263.17 (-0.07%)
CGC   26.72 (-7.22%)
GE   10.12 (-0.59%)
MU   67.07 (+4.65%)
AMD   92.64 (-0.02%)
T   28.84 (+0.31%)
NIO   44.79 (-11.36%)
F   9.22 (+1.54%)
ACB   9.74 (-16.61%)
NFLX   502.68 (+2.44%)
BA   213.51 (+1.33%)
GILD   61.12 (+0.74%)
DIS   149.45 (+0.97%)
S&P 500   3,665.00 (+1.20%)
DOW   29,849.45 (+0.71%)
QQQ   303.34 (+1.24%)
AAPL   122.56 (+2.95%)
MSFT   215.83 (+0.82%)
FB   286.45 (+3.42%)
GOOGL   1,794.91 (+2.31%)
AMZN   3,209.81 (+1.32%)
TSLA   582.30 (+2.59%)
NVDA   535.32 (-0.14%)
BABA   263.17 (-0.07%)
CGC   26.72 (-7.22%)
GE   10.12 (-0.59%)
MU   67.07 (+4.65%)
AMD   92.64 (-0.02%)
T   28.84 (+0.31%)
NIO   44.79 (-11.36%)
F   9.22 (+1.54%)
ACB   9.74 (-16.61%)
NFLX   502.68 (+2.44%)
BA   213.51 (+1.33%)
GILD   61.12 (+0.74%)
DIS   149.45 (+0.97%)
S&P 500   3,665.00 (+1.20%)
DOW   29,849.45 (+0.71%)
QQQ   303.34 (+1.24%)
AAPL   122.56 (+2.95%)
MSFT   215.83 (+0.82%)
FB   286.45 (+3.42%)
GOOGL   1,794.91 (+2.31%)
AMZN   3,209.81 (+1.32%)
TSLA   582.30 (+2.59%)
NVDA   535.32 (-0.14%)
BABA   263.17 (-0.07%)
CGC   26.72 (-7.22%)
GE   10.12 (-0.59%)
MU   67.07 (+4.65%)
AMD   92.64 (-0.02%)
T   28.84 (+0.31%)
NIO   44.79 (-11.36%)
F   9.22 (+1.54%)
ACB   9.74 (-16.61%)
NFLX   502.68 (+2.44%)
BA   213.51 (+1.33%)
GILD   61.12 (+0.74%)
DIS   149.45 (+0.97%)
Log in
NASDAQ:ALXN

Alexion Pharmaceuticals Stock Forecast, Price & News

$122.23
+0.12 (+0.10 %)
(As of 12/1/2020 03:46 PM ET)
Add
Compare
Today's Range
$121.09
Now: $122.23
$124.04
50-Day Range
$114.83
MA: $122.61
$127.81
52-Week Range
$72.67
Now: $122.23
$128.57
Volume27,820 shs
Average Volume2.15 million shs
Market Capitalization$26.75 billion
P/E Ratio28.56
Dividend YieldN/A
Beta1.31
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Alexion Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596
Employees3,082

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.99 billion
Cash Flow$11.62 per share
Book Value$50.61 per share

Profitability

Net Income$2.40 billion

Miscellaneous

Market Cap$26.75 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$122.23
+0.12 (+0.10 %)
(As of 12/1/2020 03:46 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

How has Alexion Pharmaceuticals' stock price been impacted by COVID-19?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALXN stock has increased by 46.0% and is now trading at $122.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Alexion Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 8 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alexion Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Alexion Pharmaceuticals?

Wall Street analysts have given Alexion Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Alexion Pharmaceuticals
.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported $3.24 EPS for the quarter, topping the consensus estimate of $2.60 by $0.64. The biopharmaceutical company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.43 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The business's revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.79 EPS.
View Alexion Pharmaceuticals' earnings history
.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY20 earnings guidance on Thursday, October, 29th. The company provided EPS guidance of $11.70-12.00 for the period, compared to the Thomson Reuters consensus estimate of $10.96. The company issued revenue guidance of $5.90-5.95 billion, compared to the consensus revenue estimate of $5.51 billion.

What price target have analysts set for ALXN?

24 Wall Street analysts have issued 1 year target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $110.00 to $179.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $145.25 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price.
View analysts' price targets for Alexion Pharmaceuticals
.

Are investors shorting Alexion Pharmaceuticals?

Alexion Pharmaceuticals saw a decrease in short interest in October. As of October 30th, there was short interest totaling 4,230,000 shares, a decrease of 16.7% from the October 15th total of 5,080,000 shares. Based on an average daily trading volume, of 2,060,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 1.9% of the company's shares are sold short.
View Alexion Pharmaceuticals' Short Interest
.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 57, Pay $3.7M)
  • Dr. Aradhana Sarin M.D., Exec. VP & CFO (Age 45, Pay $1.5M)
  • Mr. Brian M. Goff, Exec. VP and Chief Commercial & Global Operations Officer (Age 51, Pay $1.68M)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 63, Pay $1.76M)
  • Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
  • Mr. Christopher J. Stevo CFA, Head of Investor Relations
  • Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 48)
  • Ms. Ellen V. Chiniara J.D., Esq., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 61)
  • Megan Goulart, Sr. Director of Corp. Communications
  • Becky Lillie, Interim Chief Human Experience Officer

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.27%), State Street Corp (5.09%), LSV Asset Management (1.62%), First Trust Advisors LP (0.98%), AQR Capital Management LLC (0.86%) and The Manufacturers Life Insurance Company (0.81%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson.
View institutional ownership trends for Alexion Pharmaceuticals
.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Tennessee Treasury Department, BlackRock Inc., AQR Capital Management LLC, Nuveen Asset Management LLC, Wells Fargo & Company MN, Worldquant Millennium Advisors LLC, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Alexion Pharmaceuticals
.

Which institutional investors are buying Alexion Pharmaceuticals stock?

ALXN stock was purchased by a variety of institutional investors in the last quarter, including AJO LP, Cibc World Markets Corp, Assenagon Asset Management S.A., Toronto Dominion Bank, Wedge Capital Management L L P NC, Skandinaviska Enskilda Banken AB publ, First Trust Advisors LP, and Point72 Asset Management L.P..
View insider buying and selling activity for Alexion Pharmaceuticals
.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $122.34.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $26.77 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.